Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AzentaBSP:A2ZT34 54 5-Year ROIIC % is 0.00 as of Sep. 2025. GuruFocus rates BSP:A2ZT34 with a GF Score™ of 54/100 and a GF Value™ of R$19.22 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 731 Medical Devices & Instruments companies, Azenta ranks worse than 136798.77% on this metric.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Azenta's 5-Year ROIIC % for the quarter that ended in Sep. 2025 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Azenta's 5-Year ROIIC % or its related term are showing as below:
BSP:A2ZT34's 5-Year ROIIC % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.79 * Ranked among companies with meaningful 5-Year ROIIC % only.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Azenta 5-Year ROIIC % Related Terms
Azenta 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Azenta's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:A2ZT34 vs KMTS, STAA, BLFS: 5-Year ROIIC % Comparison
For the Medical Instruments & Supplies subindustry, Azenta's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Azenta 5-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Azenta's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Azenta's 5-Year ROIIC % falls into.
Azenta's 5-Year ROIIC % for the quarter that ended in Sep. 2025 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( -0 (Sep. 2025) - -126.9342 (Sep. 2020) )
/
( 8776.78 (Sep. 2025) - 6671.975 (Sep. 2020) )
=
/
2104.805
=
0.00%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Azenta (BSP:A2ZT34) has a 5-Year ROIIC % of 0.00 as of Sep. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Azenta and its competitors. According to the industry distribution chart, Azenta ranks #999999 out of 731 companies in the Medical Devices & Instruments industry.
Is Azenta's 5-Year ROIIC % too high?
Azenta's current 5-Year ROIIC % is 0.00. Based on the distribution chart, Azenta ranks #999999 out of 731 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Azenta has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Azenta's 5-Year ROIIC % compare to KMTS and STAA?
According to the Medical Devices & Instruments industry distribution chart, Azenta ranks #999999 out of 731 companies for 5-Year ROIIC %. This places Azenta in the lower half of its industry. The industry median 5-Year ROIIC % is 0.79. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Medical Devices & Instruments company?
The median 5-Year ROIIC % among Medical Devices & Instruments companies is 0.79, based on 731 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Azenta and its competitors. For the Medical Devices & Instruments industry, the median 5-Year ROIIC % is 0.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Azenta's current 5-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Azenta stock overvalued right now?
Based on GuruFocus' analysis, Azenta (BSP:A2ZT34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$19.22, compared to a current price of R$14.16 — trading 26.3% below its estimated fair value. The current 5-Year ROIIC % is 0.00. Azenta's overall GF Score™ is 54/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Azenta (BSP:A2ZT34), the current 5-Year ROIIC % is 0.00 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Azenta (BSP:A2ZT34) Overvalued in 2026?
Based on GuruFocus' analysis, Azenta stock appears to be undervalued.
The current stock price of R$14.16 is trading 26.3% below its estimated GF Value™ of R$19.22.
GuruFocus considers Azenta to be Modestly Undervalued.
Key valuation signals for BSP:A2ZT34:
5-Year ROIIC %: 0.00
GF Value™: R$19.22 vs. price of R$14.16 (26.3% below fair value)
No single metric tells the full story. See the BSP:A2ZT34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
54GF Score
Get the complete analysis for BSP:A2ZT34
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:A2ZT34 has been successfully added to your 
